Recombinant Human Siglec-2/CD22 Protein

• Description:

  Recombinant Human Siglec-2/CD22 Protein_x000D_ Catalog number: B2019195_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 75.2 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20°C_x000D_ Keywords: SIGLEC-2 Protein, Human; SIGLEC2 Protein, Human_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Shi S, Zhong H, Ma L, Nong J, Bai AB, Chen FL, Wu JM. [Optimal expression and activity detection of recombinant, chimeric and genetically engineered tetravalent anti-human CD22 antibodies in P.pastoris] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jun;28(6):629-32._x000D_ 2: Wong KL, Li Z, Ma F, Wang D, Song N, Chong CH, Luk KK, Leung SO. SM03, an Anti-CD22 Antibody, Converts Cis-to-Trans Ligand Binding of CD22 against α2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases J Immunol. 2022 Jun 15;208(12):2726-2737._x000D_ 3: Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia Hematology Am Soc Hematol Educ Program. 2012;2012:660-6._x000D_ 4: Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia Leuk Lymphoma. 2009 Oct;50 Suppl 1(Suppl 1):32-7._x000D_ 5: Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH, Clark EA. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation J Exp Med. 1996 Feb 1;183(2):547-60._x000D_ 6: Ruella M, June CH. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You Curr Hematol Malig Rep. 2016 Oct;11(5):368-84._x000D_ 7: Wu CM, Roth TL, Baglaenko Y, Ferri DM, Brauer P, Zuniga-Pflucker JC, Rosbe KW, Wither JE, Marson A, Allen CDC. Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins J Immunol Methods. 2018 Jun;457:33-40._x000D_ 8: Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound J Exp Med. 2002 May 6;195(9):1207-13._x000D_ 9: La Cava A. Targeting B cells with biologics in systemic lupus erythematosus Expert Opin Biol Ther. 2010 Nov;10(11):1555-61._x000D_ 10: Toda M, Akita K, Inoue M, Taketani S, Nakada H. Down-modulation of B cell signal transduction by ligation of mucins to CD22 Biochem Biophys Res Commun. 2008 Jul 18;372(1):45-50. _x000D_ _x000D_ Products Related to Recombinant Human Siglec-2/CD22 Protein can be found at Proteins

• Short Description:

  Catalog Number: B2019195 (50 µg)_x000D_ Recombinant Human Siglec-2/CD22 Protein is a laboratory-produced version of the extracellular domain of the human Siglec-2 protein, also known as CD22. It is primarily expressed on B cells and plays a crucial role in B cell signaling and function, acting as an inhibitory receptor to modulate B cell activation. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3